BioCentury
ARTICLE | Clinical News

Azeliragon: Additional Phase IIb data

August 1, 2016 7:00 AM UTC

Additional data from an 18-month, double-blind, U.S. Phase IIb trial in 399 patients with mild to moderate AD showed that once-daily 5 mg oral azeliragon significantly delayed time to cognitive deteri...